Dyne Therapeutics, Inc.
DYNNASDAQHealthcareBiotechnology
As of Oct 15, 2026 close
- Market cap
- $2.53B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $14.00$27.31
- Volume (live)
- -
- Avg. volume (3M)
- 3.69M
Dyne Therapeutics (DYN) Stock Price & Financial Analysis
Dyne Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $14.13 - $15.49 |
|---|---|
| 52-Week High | $27.31 |
| 52-Week Low | $14.00 |
| Open | $15.21 |
| Volume (last close) | 2.86M |
| Average Volume (3M) | 3.69M |
| 50-Day MA | $20.98 |
|---|---|
| 200-Day MA | $19.45 |
| 1-Year Change | −6.82% |
| Market Cap | 2.53B |
|---|---|
| Shares Outstanding | 165.45M |
| Price to Book (P/B) | 3.61 |
| EV/EBITDA | -4.16 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 16, 2026. Data sources and methodology
Dyne Therapeutics at a Glance
As of the Oct 16, 2026 close, Dyne Therapeutics (DYN) has a market capitalization of $2.53B.
As of its latest reported balance sheet, it holds $676.11M in cash and securities against $204.69M of debt, a net cash position of $471.42M.
Dyne Therapeutics does not currently pay a dividend.
The share price is down 6.8% over the past year. At $14.25 (the Oct 16, 2026 close) it sits near the bottom of its 52-week range of $14.00 to $27.30, below its 200-day moving average of $19.45.
Based on 15 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $34.67, 143.3% above the Oct 16, 2026 close.
Frequently Asked Questions About Dyne Therapeutics
What is the current stock price for DYN?
As of the Oct 16, 2026 close, DYN stock trades at $14.25. The 52-week range is $14.00–$27.31, with a day range of $14.13–$15.49.
What is the P/E ratio for DYN?
The P/E ratio (Price-to-Earnings) for DYN is shown in the Key Statistics section. This valuation metric helps compare Dyne Therapeutics, Inc. to industry peers.
Does DYN pay dividends?
Dyne Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for DYN?
Based on ratings from 15 professional analysts over the last 90 days, the consensus for DYN is Buy. The average 12-month price target is $34.67, a 143.3% upside from the Oct 16, 2026 close of $14.25.
What is the market cap of DYN?
As of the Oct 16, 2026 close, Dyne Therapeutics's market capitalization is $2.36B, classifying it as a mid-cap company. Dyne Therapeutics operates in the Healthcare sector within the Biotechnology industry.